Alzheimer's Association Welcomes U.S. FDA Approval of Kisunla
July 03, 2024
July 03, 2024
CHICAGO, Illinois, July 3 -- The Alzheimer's Association issued the following news release on July 2, 2024:
The Alzheimer's Association celebrates today's U.S. Food and Drug Administration (FDA) action to approve Kisunla(TM) (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer's disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer's disease, with confirmed amyloid plaques.
The Alzheimer's Association celebrates today's U.S. Food and Drug Administration (FDA) action to approve Kisunla(TM) (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer's disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer's disease, with confirmed amyloid plaques.